Biodegradable solid lipid nanoparticle flocculates for pulmonary delivery of insulin

Journal of Biomedical Nanotechnology

Volumn 8, Issue 5, 2012, Pages 834-842

  Yang, Xiaoyan ^a   Liu, Yongjun ^a   Liu, Chunxi ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Charge interaction; Hypoglycemic effect; Insulin; Pulmonary delivery; Relative pharmacological bioavailability; Solid lipid nanoparticle

Indexed keywords

CHARGE INTERACTIONS; HYPOGLYCEMIC EFFECT; PULMONARY DELIVERY; RELATIVE PHARMACOLOGICAL BIOAVAILABILITY; SOLID LIPID NANOPARTICLE (SLN);

BIOCHEMISTRY; EMULSIFICATION; INSULIN; POWDERS;

NANOPARTICLES;

INSULIN; SOLID LIPID NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENSITY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRY POWDER; EMULSION; FLOCCULATION; FRACTIONATION; HYPOGLYCEMIA; NONHUMAN; RAT; STATIC ELECTRICITY;

ADMINISTRATION, INHALATION; ANIMALS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; FLOCCULATION; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; NANOCAPSULES; RATS; RATS, WISTAR; STREPTOZOCIN; TREATMENT OUTCOME;

EID: 84865142230     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1429     Document Type: Article

References (45)

1. R. Siekmeier and G. Scheuch, Inhaled insulin-Does it become reality? J. Physiol. Pharmacol. 59, 81 (2008).
2. R. Bi, W. Shao, Q. Wang, and N. Zhang, Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J. Biomed. Nanotechnol. 5, 84 (2009).
3. L. Cruz, E. Fattal, L. Tasso, G. C. Freitas, A. B. Carregaro, and S. Guterres, Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J. Control. Release 2, 370 (2011).
4. H. Hamishehkar, J. Emami, A. R. Najafabadi, K. Gilani, M. Minaiyan, and H. Mandavi, Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int. J. Pharm. 389, 74 (2010).
5. R. I. Henkin, Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: Mechanisms of action. Nutrition 26, 33 (2010).
6. F. Ungaro, R. D. D. V. Bianca, C. Giovino, A. Miro, R. Sorrentino, and F. Quaglia, Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs. J. Control. Release 135, 25 (2009).
7. F. Andrade, M. Videira, D. Ferreira, and B. Sarmento, Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine 6, 123 (2011).
8. L. A. Dellamary, T. E. Tarara, D. J. Smith, C. H. Woelk, A. Adractas, and M. L. Costello, Hollow porous particles in metered dose inhalers. Pharm. Res. 17, 168 (2000).
9. Y. Yang, N. Bajaj, P. Xu, K. Ohn, M. D. Tsifansky, and Y. Yeo, Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30, 1947 (2009).
10. Y. Z. Li, X. Sun, T. Gong, J. Liu, J. A. Zuo, and Z. R. Zhang, Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm. Res. 27, 1977 (2010).
11. L. Wu, M. Al-Haydari, and S. R. da Rocha, Novel propellant-driven inhalation formulations: Engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. Eur. J. Pharm. Sci. 33, 146 (2008).
12. S. A. Shoyele and S. Cawthorne, Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug. Deliv. Rev. 58, 1009 (2006).
13. L. Wu and S. R. da Rocha, Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: A colloidal probe microscopy investigation. Langmuir 23, 12104 (2007).
14. J. Suh, K. L. Choy, S. K. Lai, J. S. Suk, B. C. Tang, S. Prabhu, and J. Hanes, PEGylation of nanoparticles improves their cytoplasmic transport. Int. J. Nanomedicine 2, 735 (2007).
15. I. M. El-Sherbiny, S. McGill, and H. D. C. Smyth, Swellable microparticles as carriers for sustained pulmonary drug delivery. J. Pharm. Sci. 99, 2343 (2010).
16. P. Selvam, I. M. El-Sherbiny, and H. D. C. Smyth, Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. J. Aerosol. Med. Pulm. Drug. Deliv. 24, 25 (2011).
17. H. Kim, H. Park, J. Lee, T. H. Kim, E. S. Lee, K. T. Oh, K. C. Lee, and Y. S Youn, Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 32, 1685 (2011).
18. D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer, Large porous particles for pulmonary drug delivery. Science 276, 1868 (1997).
19. H. F. Salem, M. E. Abdelrahim, K. A. Eid, and M. A. Sharaf, Nano-sized rods agglomerates as a new approach for formulation of a dry powder inhaler. Int. J. Nanomedicine 6, 311 (2011).
20. N. El-Gendy, V. Desai, and C. Berkland, Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J. Pharm. Innov. 32, 1 (2010).
21. J. Todoroff and R. Vanbever, Fate of nanomedicines in the lungs. Curr. Opin. Colloid. In. 16, 246 (2011).
22. I. M. E-Sherbiny and H. D. C. Smyth, Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) Self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int. J. Pharm. 395, 132 (2010).
23. L. J. Shi, C. J. Plumley, and C. Berkland, Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 23, 10897 (2007).
24. R. L. Frozza, A. Bernardi, K. Paese, J. B. Hoppe, T. Silva, A. M. O. Battastini, A. R. Pohlmann, S. S. Guterres, and C. Salbego, Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 6, 694 (2010).
25. D. Singodia, S. Talegaonkar, R. K. Khar, and P. R. Mishra, Novel polymer coupled lipid nanoparticle of paclitaxel with synergistic enhanced efficacy against cancer. J. Biomed. Nanotechnol. 7, 125 (2011).
26. R. Paliwal, S. Rai, and S. P. Vyas, Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J. Biomed. Nanotechnol. 7, 130 (2011).
27. A. F. Ourique, S. Azoubel, C. V. Ferreira, C. B. Silva, M. C. L. Marchiori, A. R. Pohlmann, S. S. Guterres, and R. C. R. Beck, Lipid-core nanocapsules as a nanomedicine for parenteral administration of tretinoin: Development and in vitro antitumor activity on human myeloid leukaemia cells. J. Biomed. Nanotechnol. 6, 214 (2010).
28. S. G. Potta, S. Minemi, R. K. Nukala, C. Peinado, D. A. Lamprou, A. Urquhart, and D. Douroumis, Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs. J. Biomed. Nanotechnol. 6, 634 (2010).
29. J. Kristl, K. Teskac, and P. A. Grabnar, Current view on nanosized solid lipid carriers for drug delivery to the skin. J. Biomed. Nanotechnol. 6, 529 (2010).
30. K. K. Singh and P. Pople, Safer than safe: Lipid nanoparticulate encapsulation of tacrolimus with enhanced targeting and improved safety for atopic dermatitis. J. Biomed. Nanotechnol. 7, 40 (2011).
31. P. A. Patel and V. B. Patravale, Ambionp: Solid lipid nanoparticles of amphotericin B for oral administration. J. Biomed. Nanotechnol. 7, 632 (2011).
32. S. G. Potta, S. Minemi, R. K. Nukala, C. Peinado, D. A. Lamprou, A. Urquhart, and D. Douroumis, Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs. J. Biomed. Nanotechnol. 6, 634 (2010).
33. S. Onoue, K. Kuriyama, A. Uchida, T. Mizumoto, and S. Yamada, Inhalable sustained-release formulation of glucagon: In vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity. Pharm. Res. 28, 1157 (2011).
34. L. Mazzarino, L. F. C. Silva, J. C. Curta, M. A. Licínio, A. Costa, L. K. Pacheco, J. M. Siqueira, J. Montanari, E. Romero, J. Assreuy, M. C. Santos-Silva, and E. Lemos-Senna, Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: An in vitro and in vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study. J. Biomed. Nanotechnol. 7, 406 (2011).
35. H. Liu, T. Gong, H. L. Fu, C. G. Wang, X. L. Wang, Q. Chen, Q. Zhang, Q. He, and Z. Zhang, Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 356, 333 (2008).
36. J. Liu, T. Gong, C. Wang, Z. Zhong, and Z. Zhang, Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int. J. Pharm. 340, 153 (2007).
37. N. El-Gendy, E. M. Gorman, E. J. Munson, and C. Berkland, Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.J. Pharm. Sci. 98, 2731 (2009).
38. N. El-Gendy and C. Berkland, Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 26, 1752 (2009).
39. R. Bi, W. Shao, Q. Wang, and N. Zhang, Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug. Target. 16, 639 (2008).
40. Q. Zhang, Z. Shen, and T. Nagai, Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm. 218, 75 (2001).
41. H. Hamishehkar, J. Emami, A. R. Najafabadi, K. Gilani, M. Minaiyan, K. Hassanzadeh, H. Mahdavi, M. Koohsoltani, and A. Nokhodchi, Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm. Drug. Dispos. 31, 189 (2010).
42. C. Bosquillon, C. Lombry, V. Preat, and R. Vanbever, Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70, 329 (2001).
43. M. R. A. Alex, A. J. Chacko, S. Jose, and E. B. Souto, Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 42, 11 (2011).
44. X. Fang, J. Wang, H. Zhou, X. Jiang, G. Zhang, and D. Zhang, Multiple response optimization of spray-drying process for the preparation of salvianolic acids microparticles and evaluation for potential application in dry powder inhalation. Dry. Technol. 29, 573 (2011).
45. N. El-Gendy and C. Berkland, Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 26, 1752 (2009).